Welcome to our dedicated page for Biomark Diagnostics news (Ticker: BMKDF), a resource for investors and traders seeking the latest updates and insights on Biomark Diagnostics stock.
BioMark Diagnostics Inc. (BMKDF) is a pioneering developer of liquid biopsy solutions using metabolomics and machine learning for early cancer detection. This page serves as the definitive source for verified corporate news, research breakthroughs, and regulatory developments.
Investors and researchers will find timely updates on clinical trial progress, intellectual property expansions, and strategic collaborations with leading medical institutions. Our curated collection includes press releases on assay validations, peer-reviewed study publications, and conference participation details.
The news archive features essential updates across three key areas: 1) Technology advancements in blood-based cancer detection platforms, 2) Regulatory and IP developments including recent USPTO patent grants, and 3) Clinical research milestones demonstrating diagnostic accuracy across multiple cancer types. All content is sourced directly from company filings and authorized communications.
Bookmark this page for streamlined access to BMKDF's latest scientific achievements and corporate announcements. For comprehensive analysis of how these developments impact the oncology diagnostics sector, consult our regularly updated research library.
BioMark Diagnostics (CSE: BUX, FSE: 20B, OTC: BMKDF) commemorates Rare Disease Day 2025 by highlighting its dedication to developing liquid biopsy solutions for rare conditions. The company focuses on advancing diagnostic tools for rare cancers like neuroendocrine tumors (NETs) of the lung and glioblastoma multiforme (GBM).
The company emphasizes the critical challenge of diagnostic delays in rare diseases, which can span from months to decades, with some patients never receiving accurate diagnoses. BioMark is developing advanced diagnostic assays using metabolomics and machine learning technologies to improve detection sensitivity and specificity for these conditions.
BioMark Diagnostics (CSE: BUX, OTC: BMKDF) announced a breakthrough in breast cancer diagnostics with a blood-based assay that can predict estrogen receptor (ER) status with 93% accuracy. The study, published in the International Journal of Molecular Sciences, demonstrates how the company's liquid biopsy platform combines metabolomics and machine learning to identify unique metabolic signatures for ER-positive and ER-negative tumors.
The company will present additional findings about plasma metabolomics in lobular breast cancer biomarker discovery at the 47th San Antonio Breast Cancer Symposium on December 11th, 2024. This research showcases the platform's ability to differentiate between breast cancer subtypes, specifically lobular breast cancer and ductal carcinoma.
BioMark Diagnostics (BMKDF) announced significant progress in its breast cancer detection program. The company's abstract on Lobular Breast Cancer (LBC) biomarker discovery has been accepted at the 2024 San Antonio Breast Cancer Symposium. The research demonstrates a simple, high-performing metabolite-based test for detecting LBC, which accounts for 10-15% of all breast cancers. This follows their October publication in the International Journal of Molecular Science highlighting a novel liquid biopsy assay for broader breast cancer detection. The company's platform combines metabolomics and machine learning for early cancer detection, focusing on developing accurate and accessible diagnostic tools.
BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) has published a study in Cancers titled "Metabolic Profiling of Pulmonary Neuroendocrine Neoplasms." The research, which examined 153 metabolites in 657 samples, identifies specific metabolomic biomarkers for early diagnosis and monitoring of pulmonary neuroendocrine neoplasms (NENs).
Key findings reveal altered plasma concentrations of multiple metabolites in NENs, highlighting changes in key metabolic pathways. This research contributes to understanding cancer metabolism and its potential clinical applications for NENs, offering benefits for detection, diagnosis, and predictive biomarker development.
BioMark's liquid biopsy-based technology platform provides a non-invasive method for detecting NENs and has shown clinical utility in early detection of other hard-to-detect cancers. The study was funded by a MEDTEQ+ research grant and conducted in collaboration with IUCPQ and The Metabolomics Innovation Centre (TMIC).
BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) has successfully completed a major clinical trial for its early lung cancer detection assay. The study, conducted in collaboration with IUCPQ, analyzed over 5,400 patient samples, including 2,500 archived samples and 2,900 high-risk participants. This marks the largest clinical study validating a metabolite-based assay for lung cancer screening.
CEO Rashid Bux highlighted the trial's significance, emphasizing its diverse patient pool and real-world representation. BioMark has partnered with a leading data analytics group to analyze the vast amount of data collected. The company plans to present the results at an upcoming medical conference and submit them for publication in a peer-reviewed journal, aiming to make the innovative technology available to patients as soon as possible.
BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF), a developer of liquid biopsy tests for early cancer detection, will participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York from September 9-11, 2024. CEO Rashid Bux and CSO Jean-François Haince will showcase BioMark's pipeline of liquid biopsy tests for lung cancer, breast cancer, and glioblastoma.
The company's presentation will be available on-demand through the conference portal on September 9, 2024, at 7:00 a.m. Eastern Time. BioMark will also conduct one-on-one meetings virtually. This event provides an opportunity for BioMark to connect with potential investors, partners, and industry experts as they prepare for the commercial launch of their early lung cancer assay and U.S. market entry.
BioMark Diagnostics Inc. (CSE: BUX, FSE: 20B, OTC Pink: BMKDF) has been granted U.S. Patent No. 17/895.69 by the USPTO, strengthening its liquid biopsy technology for cancer management. The patent protects BioMark's SAT1 legacy assay platform for assessing tumor velocity and treatment response in glioblastoma (GBM) and triple-negative breast cancer (TNBC) patients with specific genetic mutations.
Key points:
- GBM market size estimated at $2.80 billion in 2024, expected to reach $4.60 billion by 2029 (CAGR 8%)
- TNBC accounts for 15% of all breast cancers
- BioMark plans to launch a preclinical study for TNBC patients with BRCA mutations
- The patent enhances BioMark's position in developing cancer management solutions
BioMark Diagnostics Inc. (CSE: BUX) (OTC Pink: BMKDF) announced that collaborators from the University of Manitoba will present new research findings on glioblastoma at the 2024 GPEN Conference in Copenhagen. The presentations focus on:
1. Evaluation of hydrogel formulations for delivering siRNA to glioblastoma tumor cells
2. Examination of potential drug biomarker candidates for glioblastoma
The research highlights BioMark's liquid biopsy technology for evaluating minimal residual disease and treatment outcomes in glioblastoma. CEO Rashid Ahmed Bux emphasized their comprehensive approach, including biomarker discovery, novel drug delivery mechanisms, and potential gene knockdown treatments for glioblastoma.
FAQ
What is the current stock price of Biomark Diagnostics (BMKDF)?
What is the market cap of Biomark Diagnostics (BMKDF)?
